Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7401 - 7425 of 8028 in total
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
Matched Description: … Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. …
Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
Investigational
Matched Description: … Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently …
Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).
Investigational
Matched Description: … Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816 …
Uracil C-13 is under investigation in clinical trial NCT01677338 (Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects).
Investigational
Matched Description: … investigation in clinical trial NCT01677338 (Phase 2 Study to Evaluate the Preliminary Performance of
Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).
Investigational
Matched Description: … under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of
Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Description: … Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of
mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.
Investigational
Matched Description: … ., it is being investigated for the treatment of methylmalonic academia.[A258843] …
ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.
Investigational
Matched Description: … Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093] …
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Matched Description: … [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis …
Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. The D-stereoisomer is occasionally found in naturally produced peptides (for example, the marine venom peptide contryphan). The distinguishing...
Experimental
Matched Description: … Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet ... The distinguishing structural characteristic of tryptophan is that it contains an indole functional group …
Desmoteplase is a chemical in the saliva of vampire bats. It activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots. When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting. The enzyme is called DSPA (Desmodus rotundus...
Investigational
Matched Description: … Desmoteplase is a chemical in the saliva of vampire bats. ... Desmoteplase is a recombinant form of vampire bat DSPA (Salivary plasminogen activator alpha 1). …
Oglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection. Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by...
Investigational
Matched Description: … Oglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis ... Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration …
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Matched Description: … This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune …
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action …
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of
Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Vet approved
Matched Description: … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of
Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.
Investigational
Matched Description: … Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer …
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
Investigational
Matched Description: … S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung …
Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .
Experimental
Matched Description: … Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of
Afamitresgene autoleucel is a specific Peptide Enhanced Affinity Receptor T cell product comprised of autologous CD4 and CD8 positive T cells genetically engineered with an affinity-enhanced T cell receptor to target cancer-testis antigen MAGE-A4
Investigational
Matched Description: … Afamitresgene autoleucel is a specific Peptide Enhanced Affinity Receptor T cell product comprised of
5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases (also called methionine synthases).
Investigational
Nutraceutical
Matched Description: … 5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. …
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. …
Displaying drugs 7401 - 7425 of 8028 in total